EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study

Tianshu Gu iD, Yang Chen, Nan Zhang, Uazman Alam, Riccardo Proietti, Tong Liu iD, Kang-Yin Chen, Gregory Y H Lip

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70687 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Tianshu Gu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Live…. Hauptthemen laut MEDLINE: PCSK9 Inhibitors, Atherosclerosis, Antibodies, Monoclonal, Humanized, Mental Disorders. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

PCSK9 inhibitors reduce major cardiovascular events in randomized trials of atherosclerotic cardiovascular disease (ASCVD), but real‐world neuropsychiatric safety remains uncertain.

Methods

In a propensity score–matched retrospective cohort study using the TriNetX U.S. Federated Research Network, adults with established ASCVD initiating alirocumab or evolocumab between 2017 and 2024 were matched 1:1 to statin‐monotherapy initiators. The 12‐month primary analysis assessed major adverse cardiovascular events (MACE: myocardial infarction, heart failure [HF], ischaemic stroke, all‐cause death), neurodegenerative disease (dementia, Parkinson's disease) and psychiatric disorders (psychosis, bipolar disorder, depression, anxiety), with Bonferroni correction and negative control. Secondary analyses examined individual agents, ASCVD subtypes, statin use, an intensified lipid‐lowering comparator and extended follow‐up.

Results

Among 60 885 matched pairs (mean age 70 years; 61% male), PCSK9 inhibitor therapy was associated with lower 12‐month risks of MACE (HR 0.84, 95% CI 0.80–0.88), myocardial infarction (HR 0.82, 0.79–0.86), HF (HR 0.87, 0.83–0.92) and all‐cause mortality (HR 0.40, 0.37–0.43); ischaemic stroke did not differ. After Bonferroni correction, no neurodegenerative association remained significant. PCSK9 inhibitor use was associated with higher risks of any psychiatric diagnosis (HR 1.33, 1.25–1.42), depression (HR 1.44, 1.28–1.61) and anxiety (HR 1.39, 1.28–1.50), persisting in secondary analyses; negative control outcomes did not differ.

Conclusions

PCSK9 inhibitor use was associated with favourable cardiovascular outcomes and no clear neurodegenerative harm, but higher rates of depression and anxiety. Given the observational design and potential residual confounding, statin‐intolerance‐related treatment selection and surveillance bias, these findings should be interpreted as hypothesis‐generating and warrant further prospective evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PCSK9 InhibitorsAtherosclerosisAntibodies, Monoclonal, HumanizedMental DisordersAnticholesteremic AgentsCardiovascular DiseasesHumansRetrospective StudiesMaleAgedFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsMiddle AgedProprotein Convertase 9Propensity Score

Stichwörter der Autor:innen

PCSK9 inhibitorsatherosclerotic cardiovascular diseaseneuropsychiatric disordersreal‐world evidence

Substanzen

PCSK9 InhibitorsAntibodies, Monoclonal, HumanizedPCSK9 protein, humanevolocumabalirocumabHydroxymethylglutaryl-CoA Reductase InhibitorsAnticholesteremic AgentsProprotein Convertase 9

Autor:innen und Institutionen

  • Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, UK.
  • Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular disease, Department of Cardiology, Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin, China.
  • Department of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, UK.
  • Liverpool Centre for Cardiovascular Sciences, University of Liverpool and Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
  • Centre for Biomechanics and Rehabilitation Technologies, Staffordshire University, Stoke-on-Trent, UK.
  • Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

ORCID-Profile: Tianshu Gu, Tong Liu

Zitieren

APA

Gu, T., Chen, Y., Zhang, N., Alam, U., Proietti, R., Liu, T., Chen, K. Y., & Lip, G. Y. H. (2026). Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70687

Vancouver

Gu T, Chen Y, Zhang N, Alam U, Proietti R, Liu T, et al. Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70687

BibTeX
@article{Gu2026,
  author = {Gu, Tianshu and Chen, Yang and Zhang, Nan and Alam, Uazman and Proietti, Riccardo and Liu, Tong and Chen, Kang-Yin and Lip, Gregory Y H},
  title = {Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70687}
}
Kostenlos starten →